Treatment of men with lower urinary tract symptoms and overactive bladder.
Young
James G
JG
Subramonian
Kesavapilla
K
D000317:Adrenergic alpha-Antagonists / Q000191:economics / Q000627:therapeutic use*; D000368:Aged; D001559:Benzhydryl Compounds / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003408:Cresols / Q000191:economics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000191:economics / Q000627:therapeutic use*; D017060:Patient Satisfaction; D010665:Phenylpropanolamine / Q000191:economics / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013449:Sulfonamides / Q000191:economics / Q000627:therapeutic use; D000077409:Tamsulosin; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D053202:Urinary Incontinence, Urge / Q000188:drug therapy
D000317:Adrenergic alpha-Antagonists; D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D013449:Sulfonamides; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; D000077409:Tamsulosin